EGFR and neoplasm: AXL-CAR-T inhibited tumor growth in the aforementioned model, enhanced the therapeutic efficacy of anti-vascular endothelial growth factor (VEGF) and anti-epidermal growth factor receptor (EGFR) small molecule inhibitors as well as chemotherapy in TNBC, and altered the tumor mesenchyme by modulating the TNBC-associated vascular system and immune cell function (Ye et al., 2010).